Drug Search Results
More Filters [+]

TBX-1400

Alternative Names: tbx-1400, tbx1400, tbx 1400
Latest Update: 2020-10-08
Latest Update Note: Clinical Trial Update

Product Description

stem cells for Severe Combined Immunodeficiency (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02860559)

Mechanisms of Action: Stem Cell Therapy

Novel Mechanism: Yes

Modality: Cell Therapy

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Taiga Biotechnologies
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for TBX-1400

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Severe Combined Immunodeficiency

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

TBX-1400-001

P1

Unknown status

Severe Combined Immunodeficiency

2024-02-01

22%

Recent News Events

Date

Type

Title